SOPHiA Genetics SA P/E Ratio

SOPHiA Genetics SA (SOPH) currently reports a P/E ratio of -6.84. That is below the Healthcare sector average of 24.78. Use the charts on this page to explore SOPHiA Genetics SA's P/E ratio history and peer comparisons.

SOPHiA Genetics SA's P/E ratio of -6.84 is lower than the Healthcare sector average of 24.78. That is roughly 127.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates SOPHiA Genetics SA's market price to a fundamental measure such as earnings, sales, or book value. At -6.84, SOPH can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -6.84, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for SOPHiA Genetics SA, and consider following SOPH for alerts when major investors trade the stock.

SOPHiA Genetics SA is classified in the Healthcare sector. On P/E ratio, it currently shows -6.84 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SOPH with unrelated industries.